» Articles » PMID: 22675560

Histological and Molecular Evaluation of Patient-derived Colorectal Cancer Explants

Overview
Journal PLoS One
Date 2012 Jun 8
PMID 22675560
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Mouse models have been developed to investigate colorectal cancer etiology and evaluate new anti-cancer therapies. While genetically engineered and carcinogen-induced mouse models have provided important information with regard to the mechanisms underlying the oncogenic process, tumor xenograft models remain the standard for the evaluation of new chemotherapy and targeted drug treatments for clinical use. However, it remains unclear to what extent explanted colorectal tumor tissues retain inherent pathological features over time. In this study, we have generated a panel of 27 patient-derived colorectal cancer explants (PDCCEs) by direct transplantation of human colorectal cancer tissues into NOD-SCID mice. Using this panel, we performed a comparison of histology, gene expression and mutation status between PDCCEs and the original human tissues from which they were derived. Our findings demonstrate that PDCCEs maintain key histological features, basic gene expression patterns and KRAS/BRAF mutation status through multiple passages. Altogether, these findings suggest that PDCCEs maintain similarity to the patient tumor from which they are derived and may have the potential to serve as a reliable preclinical model that can be incorporated into future strategies to optimize individual therapy for patients with colorectal cancer.

Citing Articles

Protein Folding Stability Profiling of Colorectal Cancer Chemoresistance Identifies Functionally Relevant Biomarkers.

Quan B, Bailey M, Mantyh J, Hsu D, Fitzgerald M J Proteome Res. 2023; 22(6):1923-1935.

PMID: 37126456 PMC: 10441206. DOI: 10.1021/acs.jproteome.3c00045.


An autologous humanized patient-derived xenograft (PDX) model for evaluation of nivolumab immunotherapy in renal cell cancer: a case report.

Kang Y, Armstrong A, Hsu D Stem Cell Investig. 2022; 9:8.

PMID: 36393918 PMC: 9659479. DOI: 10.21037/sci-2022-029.


Gene interaction perturbation network deciphers a high-resolution taxonomy in colorectal cancer.

Liu Z, Weng S, Dang Q, Xu H, Ren Y, Guo C Elife. 2022; 11.

PMID: 36345721 PMC: 9643007. DOI: 10.7554/eLife.81114.


Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies.

Lidsky M, Wang Z, Lu M, Liu A, Hsu S, McCall S NPJ Precis Oncol. 2022; 6(1):75.

PMID: 36274097 PMC: 9588766. DOI: 10.1038/s41698-022-00320-5.


Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression.

Hwang B, Tsao L, Acharya C, Trotter T, Agarwal P, Wei J J Immunother Cancer. 2022; 10(3).

PMID: 35361727 PMC: 8971789. DOI: 10.1136/jitc-2021-003721.


References
1.
Johnson W, Li C, Rabinovic A . Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2006; 8(1):118-27. DOI: 10.1093/biostatistics/kxj037. View

2.
Fichtner I, Slisow W, Gill J, Becker M, Elbe B, Hillebrand T . Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer. 2004; 40(2):298-307. DOI: 10.1016/j.ejca.2003.10.011. View

3.
Kendall S, Adam S, Counter C . Genetically engineered human cancer models utilizing mammalian transgene expression. Cell Cycle. 2006; 5(10):1074-9. DOI: 10.4161/cc.5.10.2734. View

4.
Arcaroli J, Touban B, Tan A, Varella-Garcia M, Powell R, Eckhardt S . Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin Cancer Res. 2010; 16(16):4165-77. PMC: 3805460. DOI: 10.1158/1078-0432.CCR-10-0066. View

5.
Kim M, Osada T, Barry W, Yang X, Freedman J, Tsamis K . Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancer. Mol Cancer Ther. 2012; 11(7):1500-1509. PMC: 4521598. DOI: 10.1158/1535-7163.MCT-11-0937. View